Daito Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Daito Pharmaceutical Company Limited with three other
companies in this sector in Japan:
Taiko Pharmaceutical Company., Limited
sales of 10.42 billion Japanese Yen [US$96.06 million]
of which 53%
was Medicine Goods),
Koa Shoji Holdings Co Ltd
(15.21 billion Japanese Yen [US$140.20 million]
of which 72%
was Drug substance sales business), and
JCR Pharmaceuticals Co., Ltd.
(23.16 billion Japanese Yen [US$213.54 million]
of which 99%
was Pharmaceutical Business).
During the year ended May of 2019, sales at
Daito Pharmaceutical Company Limited were ¥41.13 billion (US$379.26 million).
increase of 3.2%
versus 2018, when the company's sales were ¥39.88 billion.
This was the fifth consecutive year of sales increases at Daito Pharmaceutical Company Limited
(and since 2014, sales have increased a total of 32%).
Sales of Drug Substance saw an increase
5.9% in 2019, from
¥20.85 billion to ¥22.08 billion.
Not all segments of Daito Pharmaceutical Company Limited experienced an increase in sales in 2019:
sales of Health Food Other fell 6.2% to ¥300.75 million.
(However, this segment's sales were only a very small portion of the company's overall sales).